Actuate Therapeutics (ACTU) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical business developing cancer therapies through inhibition of GSK-3; lead asset elraglusib is an ATP-competitive small molecule exclusively licensed from the University of Illinois Chicago and Northwestern University.

• Elraglusib is being developed as an IV injection and oral tablet; more than 500 patients have received the injection in Phase 1 and Phase 2 studies.

• Oral tablet Phase 1/2 study cleared by FDA after an April 2026 IND filing; planned dose escalation will identify MTD and RP2D in adults with advanced, refractory cancers.

Financial performance and metrics

• No product-sales revenue since inception; significant operating losses and negative operating cash flows, with further losses expected as clinical development advances.

• At June 30, 2026, cash and cash equivalents were $4.43 million and working capital was $942,745.

• June 30, 2026 net tangible book value was $0.99 million, or $0.04 per share; adjusted value after the base offering was estimated at $39.6 million, or $0.45 per share.

Use of proceeds and capital allocation

• Net proceeds designated for working capital and general corporate purposes; no specific allocations, with management retaining broad discretion over use and timing.